Dr. Sarah Premji, Dr. Reshma Mahtani & Dr. Eleftherios Mamounas - Expanding T-DXd Across HER2 + Breast Cancer

How is trastuzumab deruxtecan (T-DXd) reshaping treatment across early-stage and metastatic HER2-positive breast cancer?Dr. Sarah Premji, Dr. Reshma Mahtani, and Dr. Eleftherios "Terry" Mamounas discuss the practice-changing implications of DESTINY-Breast11, DESTINY-Breast05, and DESTINY-Breast09, exploring how T-DXd is moving earlier in the treatment paradigm and influencing decision-making from the neoadjuvant setting through first-line metastatic disease. The conversation examines pathologic complete response (pCR), residual disease management, toxicity monitoring, multidisciplinary care, and the evolving role of biomarkers in treatment personalization.Topics include:• DESTINY-Breast11 and neoadjuvant T-DXd strategies• Pathologic complete response (pCR) and treatment de-escalation• Residual disease management after neoadjuvant therapy• DESTINY-Breast05 and adjuvant T-DXd in high-risk disease• Monitoring and managing interstitial lung disease (ILD)• Patient education, supportive care, and toxicity mitigation• Multidisciplinary collaboration in HER2-positive breast cancer care• DESTINY-Breast09 and first-line metastatic treatment advances• T-DXd plus pertuzumab in metastatic HER2-positive disease• Future roles for ctDNA and biomarker-guided treatment decisionsAs HER2-directed therapies continue to evolve, clinicians are increasingly challenged to determine when to introduce the most effective treatments, how to manage long-term toxicities, and how to personalize care across the entire disease continuum.Watch more expert oncology discussions from Community Health Media and subscribe for future conversations with leading oncology experts.